USANew treatments and approvals
Once-weekly injection navepegritide receives accelerated approval for achondroplasia in the USA
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA granted accelerated approval to the drug navepegritide on February 27, 2026. The approval is for children aged 2 years and older with achondroplasia whose growth plates are open. The drug aims to increase growth in height. It is injected under the skin once a week. Under accelerated approval, lasting benefit must be confirmed in new studies.
What does it mean for patients and families?
A weekly option for achondroplasia has been approved in the USA. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Treatment decisions are made with a doctor.
Source
ABD Gıda ve İlaç Dairesi (FDA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Achondroplasia
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.